

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Christopher Browning Hurt</b>	POSITION TITLE <b>Clinical Instructor in Infectious Diseases</b>		
eRA COMMONS USER NAME <b>christopher_hurt</b>			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Florida, Gainesville, FL	B.S.	12/98	Biochemistry & Molecular Biology
University of Florida College of Medicine, Gainesville, FL	M.D.	05/03	Medicine
Brown University / Rhode Island and The Miriam Hospitals, Providence, RI		2003-06	Internship & Residency in Internal Medicine
American Board of Internal Medicine, Internal Medicine Specialty Certification		08/06	Internal Medicine
University of North Carolina at Chapel Hill, Chapel Hill, NC		2006-09	Fellowship in Infectious Diseases
American Board of Internal Medicine, Infectious Diseases Subspecialty Certification		10/09	Infectious Diseases

### A. PERSONAL STATEMENT

As a junior faculty member at UNC, my career development plan is directed toward becoming a clinical scientist in the field of HIV epidemiology and *secondary* prevention – the prevention of forward transmission of the virus from those already living with HIV. This requires not only the maintenance of skills in the care and management of patients with HIV and AIDS, but also the application of behavioral science and epidemiology to address real-world questions of importance to the future of the HIV epidemic. I feel strongly that our only real hope of ending the epidemic will come not from the administration of antiretrovirals alone, but through synergy among varied biomedical and behavioral interventions.

### B. POSITIONS AND HONORS

#### Positions

2010 – present Clinical Instructor, Division of Infectious Diseases, UNC-Chapel Hill

#### Certifications

2006 Diplomate in Internal Medicine, American Board of Internal Medicine (through 2016)

2009 Diplomate in Infectious Diseases, American Board of Internal Medicine (through 2019)

#### Committees and Service

2009 – present NIAID Influenza Research Collaboration (IRC) Combination Therapy Focus Group

#### Professional Memberships and Other Experience

2003 – present American College of Physicians (ACP), Member

2006 – present Infectious Diseases Society of America (IDSA), Member

2006 – present HIV Medicine Association (HIVMA), Member

#### Awards

2006 – 2009 NIH/NIAID T32 Training Grant in Sexually Transmitted Diseases and AIDS

2007 Bristol-Myers Squibb Virology Fellowship

2008 University of North Carolina K30 Scholars Clinical Research Training Program

2009 *Clinical Infectious Diseases* Award for Outstanding Review (with Joseph Eron, Jr.)

2010 North Carolina Translational and Clinical Science Institute TraC\$ 10K Pilot Grant Award

2010 KL2 Scholar, UNC Multidisciplinary Clinical Research Career Development Program

### Honors

1999 Phi Beta Kappa, University of Florida (UF)  
2001 Equal Access Clinic Distinguished Service Award  
2003 Award for Excellence in Internal Medicine  
American College of Physicians, Florida Chapter  
2003 Gold Humanism Honor Society, Chapman Chapter, UF College of Medicine  
2003 Honors for Special Achievement (at graduation), UF College of Medicine  
2009 Reviewer for *Antiviral Therapy, AIDS and Behavior*, and *Clinical Infectious Diseases*  
2009 Reviewer for *Sexually Transmitted Diseases*

## C. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order)

### PUBLISHED MANUSCRIPTS

McInerney M, Serrano Rodriguez G, Pawlina W, **Hurt CB**, Fletcher BS, Laipis PJ, Frost SC. "Glycogen phosphorylase is activated in response to glucose deprivation but is not responsible for enhanced glucose transport in 3T3-L1 adipocytes." *Biochim Biophys Acta* 2002 Feb 15; 1570(1):53-62. PMID: [11960689](#).

**Hurt C**, Tammaro D. "The diagnostic evaluation of mononucleosis-like illnesses." *Am J Med* 2007 Oct; 120(10):911.e1-8. PMID: [17904463](#).

**Hurt CB**, McCoy SI, Kuruc J, Nelson J, Kerkau M, Fiscus S, McGee K, Sebastian J, Leone P, Pilcher CD, Hicks C, Eron J. "Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina, 1998 to 2007." *Antivir Therapy* 2009; 14(5):673-678. PMID: [19704170](#). PubMed Central PMCID: [PMC2860724](#).

McCoy SI, Miller WC, MacDonald PDM, **Hurt CB**, Leone PA, Eron JJ, Strauss RP. "Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast." *AIDS Care* 2009; 21(10):1313-20. PMID: [20024708](#).

**Hurt CB**, Matthews DD, Calabria MS, Adimora AA, Golin CE, Hightow-Weidman LB. "Sex with older partners is associated with primary HIV infection among men who have sex with men in North Carolina." *JAIDS* 2010; 54(2):185-90. PMID: [20057320](#). PubMed Central PMCID: [PMC2877753](#).

**Hurt CB**, Torrone E, Green K, Foust E, Leone P, Hightow-Weidman L. "Methamphetamine use among newly diagnosed HIV-positive young men in North Carolina, United States, from 2000 to 2005." *PLoS ONE* 2010; 5(6):e11314. PubMed PMID: [20593025](#). PubMed Central PMCID: [PMC2892509](#).

### PEER-REVIEWED ABSTRACTS

**Hurt C**, McCoy S, Kerkau M, Nelson J, Sebastian J, Kuruc J, McGee K, Lennox J, Pilcher C, Hicks C, Eron J. "Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas." 16<sup>th</sup> International HIV Drug Resistance Workshop, St. Michael, Barbados, 12-16 June 2007. (#48, *Antivir Ther* 2007;12:S55.) (<http://www.intmedpress.com/serveFile.cfm?sUID=36a5d521-cb5c-4d51-9490-936bf008c2c3> , p.75)

Torrone EA, **Hurt CB**, Green KA, Leone PA, Hightow-Weidman LB. "Race, risk, and HIV: an evolving epidemic among young men in North Carolina." 135<sup>th</sup> Annual Meeting of the American Public Health Association, Washington, D.C., 3-7 November 2007. (#157008, [http://apha.confex.com/apha/135am/techprogram/paper\\_157008.htm](http://apha.confex.com/apha/135am/techprogram/paper_157008.htm))

McCoy S, Kuruc J, Gay C, **Hurt C**, Anderson J, Pilcher C, Barnhart J, Eron J, Leone P. "Partner counseling and referral outcomes after acute HIV identification in North Carolina." 15<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, 3-6 February 2008. (#531, <http://www.retroconference.org/2008/Abstracts/30943.htm>)

Hightow-Weidman LB, Golin CE, Green KA, **Hurt CB**, Sachdeva N, Stapleton M, Adimora AA. "Project SNAP (Social Networks and Partnerships): an innovative examination into the risk behaviors, health beliefs, and psychosocial features of HIV-infected and uninfected men who have sex with men (MSM) in the South." 136<sup>th</sup> American Public Health Association Annual Meeting, San Diego, CA, 25-29 October 2008. (#181788, <http://apha.confex.com/apha/136am/webprogram/Paper181788.html>)

**Hurt CB**, Matthews DD, Calabria MS, Adimora AA, Golin CE, Hightow-Weidman LB. "Sexual Partner Age Mixing, Acute or Recent HIV Infection, and Young MSM in North Carolina." 2009 CDC National HIV Prevention Conference, Atlanta, GA, 23-26 August 2009.  
(#493/Presentation B06-3, [http://www.2009nhpc.org/doc/2009\\_NHPC\\_Abstract\\_Book.pdf](http://www.2009nhpc.org/doc/2009_NHPC_Abstract_Book.pdf) , p.96)

**Hurt CB**, Dennis A, Kuruc J, Nelson J, Sebastian J, Leone P, Pilcher C, Hicks C, Eron J. "Phylogenetic relationships among acutely and recently HIV-infected persons in North Carolina: missed opportunities for secondary prevention?" 16<sup>th</sup> International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, Rockville, MD, 29 August – 3 September 2010.

#### **D. RESEARCH SUPPORT**

##### **ACTIVE**

KL2 RR 025746      Orringer (PI)      7/1/10 – 6/30/13

*Spatial Epidemiology, Risk Behaviors, and HIV Resistance in North Carolina*

Role: Investigator and KL2 Scholar      Mentors: Emch, Eron

Purpose: Evaluate the association of HIV risk behaviors, sociodemographics, and geographic location with the acquisition of an antiretroviral-resistant strain of HIV at the time of initial infection.

#10KR71008 – NC Translational and Clinical Science (TraCS) Pilot Grant      7/28/10 – 7/1/11

*A Prospective Study to Validate the Gen-Probe APTIMA Combo2 Nucleic Acid Amplification Test for Non-Genital Gonorrhea and Chlamydia among HIV-Infected Men Who Have Sex with Men*

Role: Principal Investigator      Co-Investigators: Hightow-Weidman, Miller M

Purpose: Validate clinical use of nucleic acid amplification-based technologies for diagnosis of gonorrhea and chlamydia at anatomical sites other than the genitourinary tract.

UNC Center for AIDS Research, Social and Behavioral Science Research Core      12/1/09 – 12/31/10

*Assessing Opportunities for Sexual Transmission of Drug Resistance among HIV-Infected Men and Women Engaged in Care*

Role: Principal Investigator      Co-Investigators: Napravnik, Eron

Purpose: Secondary data analysis of ongoing sexual risk behaviors of HIV-infected patients followed at the UNC Infectious Diseases Clinic, to inform future secondary prevention efforts.

1 U01 AI069423-01      Eron (PI)      2/1/07 – 11/30/13

*UNC HIV Clinical Trials Unit (ACTG, HPTN, HVTN)*

Role: Co-Investigator      *Originally Funded*      9/1/87

Purpose: The major goals of this project are to provide an effective and efficient system to evaluate the safety and efficacy of the therapeutic interventions against HIV/AIDS and its associated conditions.

Bristol-Myers Squibb Virology Fellowship      1/1/08 – 6/30/10

*HIV-Related Risk Behavior and the Acquisition of Antiretroviral Resistance*

Role: Principal Investigator      Co-Investigators: Eron, Golin, Hightow-Weidman

Purpose: Conduct qualitative studies to explore attitudes, beliefs, and perceptions of risk behavior among men who have sex with men living with drug-resistant HIV.

ID#33110 – Merck & Company, Inc.      8/1/09 – 12/31/10

*Efficacy and Tolerability of Raltegravir among Men and Women with HIV/Hepatitis C Co-infection*

Role: Principal Investigator

Purpose: Determine the profile of hepatotoxicity or other adverse events that developed among HIV/HCV co-infected patients receiving the integrase inhibitor, raltegravir.

**COMPLETED**

5 T32 AI 07001-30, -31, and -32 Sparling (PI)

8/1/06 – 7/31/09

*Training in Sexually Transmitted Diseases and AIDS*

Role: Trainee

Purpose: This institutional T32 training grant supports the development of clinical researchers focused on the biology, transmission, and prevention of sexually transmitted infections, including HIV.